Lisinopril vs Entresto: Entresto (sacubitril/valsartan) is generally preferred over lisinopril for many adults with chronic heart failure with reduced ejection fraction (HFrEF) because clinical trials found it reduced cardiovascular death and heart-failure hospitalization more than an ACE inhibitor. However, lisinopril remains an effective, lower-cost option for high blood pressure, post-heart-attack protection, and some patients who cannot take Entresto.
What Each Medication Is
| Feature | Lisinopril | Entresto |
|---|---|---|
| Drug class | ACE inhibitor | ARNI: sacubitril (neprilysin inhibitor) + valsartan (ARB)- goodrx |
| Main uses | High blood pressure, heart failure, reducing death risk after a heart attack. | Heart failure in adults and children older than 1 year. |
| Typical dosing | Usually once daily. | Usually twice daily. |
| Cost and availability | Generic, generally lower cost. | Brand-name medication; usually more expensive. |
| Notable side effect | Persistent dry cough is relatively characteristic. | Low blood pressure, high potassium, and dizziness are common concerns. |
Lisinopril vs Entresto: How They Work
Lisinopril blocks angiotensin-converting enzyme (ACE). This lowers angiotensin II, a hormone that narrows blood vessels and promotes fluid retention, thereby reducing blood pressure and easing the heart’s workload.
Entresto combines two actions: valsartan blocks the angiotensin receptor, while sacubitril inhibits neprilysin, increasing protective natriuretic peptides that help the body eliminate sodium and fluid. This dual mechanism is why it is called an angiotensin receptor-neprilysin inhibitor, or ARNI.
Lisinopril vs Entresto: Which Is Better for Heart Failure?
For eligible patients with HFrEF, Entresto has stronger evidence for improving hard outcomes. In the landmark PARADIGM-HF trial, Entresto was superior to the ACE inhibitor enalapril in reducing cardiovascular death and heart-failure hospitalization.
A plain-language summary of that evidence estimated that, over two years, about 13 of 100 people taking Entresto would be hospitalized for heart failure versus about 16 of 100 taking an ACE inhibitor; it also found a survival advantage with Entresto.
That does not mean lisinopril is a poor heart-failure medicine. It remains a guideline-supported ACE inhibitor and can be appropriate when Entresto is unsuitable, unaffordable, or causes intolerable effects.
When Lisinopril May Be Preferred
Lisinopril may be the better choice when a patient:
- Needs treatment for high blood pressure rather than heart failure.
- Needs a lower-cost, generic medication.
- Has a history of angioedema with sacubitril/valsartan or cannot safely use an ARNI –medicalnewstoday
- Prefers once-daily dosing or has difficulty adhering to twice-daily treatment.
- Has a contraindication to Entresto, such as recent use of an ACE inhibitor or ARB without an adequate washout period.
Lisinopril vs Entresto: When Entresto May Be Preferred
Entresto may be preferred when a patient has symptomatic chronic HFrEF and can safely tolerate it, particularly if they have had repeated hospitalizations, persistent symptoms, or reduced heart pumping function. Its proven advantage over ACE-inhibitor therapy is reduced cardiovascular death and heart-failure hospitalization.
It is also an option for eligible children over age 1 with heart failure, whereas lisinopril’s approved uses include hypertension from age 6 and heart failure/post-heart-attack indications in adults.
Safety and Interactions
Both drugs can lower blood pressure, raise potassium, and impair kidney function, so clinicians commonly monitor blood pressure, kidney function, and potassium—especially after dose changes or during illness.
Do not combine lisinopril and Entresto. Because Entresto contains valsartan, taking it with an ACE inhibitor such as lisinopril can substantially increase the risk of angioedema, a rare but potentially life-threatening swelling reaction.
Patients switching from lisinopril to Entresto need a clinician-directed washout period before starting Entresto. Do not stop, start, or overlap these medicines without prescriber guidance.
Bottom Line
For blood pressure, lisinopril is often the simpler, cheaper first-line choice. For HFrEF, Entresto is usually the more effective evidence-based option when appropriate and affordable, while lisinopril remains a valuable alternative when Entresto cannot be used.
When dealing with Lisinopril vs Entresto, the right medication depends on ejection fraction, kidney function, potassium level, blood pressure, prior angioedema, cost, and other medicines. A cardiologist or primary-care clinician should make the final selection and supervise any transition.